在新南威尔士州,抗药性淋病病例,包括抗治疗性菌株,正在急剧上升,引起对公共健康的关切。 Drug-resistant gonorrhoea cases, including treatment-resistant strains, are rising sharply in New South Wales, prompting public health concerns.

新南威尔士州抗药性淋病病例呈上升趋势,据新南威尔士州卫生部统计,2026年初报告的抗药性多药性病例从2025年的41起上升至2026年初的16起。 Drug-resistant gonorrhoea cases are rising in New South Wales, with 16 multi-drug resistant cases reported in early 2026—up from 41 for all of 2025—according to NSW Health. 有两个病例表明,主要治疗是食氯酮(efcriaxone)和阿兹罗米辛(azithromycin)的抗药性很高,引起对治疗短缺的关切。 Two cases show high-level resistance to ceftriaxone, the main treatment, and azithromycin, raising concerns about treatment shortages. 多数病例发生在悉尼的异性恋者中,包括与女性性工作者的联系。 Most cases are in Sydney among heterosexual individuals, including links to female sex workers. 感染往往在没有症状的情况下蔓延,有不孕症和其他并发症的危险。 The infection often spreads without symptoms, risking infertility and other complications. 在全国范围内,病例在过去十年中几乎翻了一番,2024年达到44 210例,男子占三分之二。 Nationally, cases nearly doubled over the past decade, reaching 44,210 in 2024, with men making up two-thirds. 在美国成功之后,研究人员正在利用AI开发新的抗生素,因为抗药性威胁到目前的治疗方案。 Researchers are using AI to develop new antibiotics, following U.S. success, as resistance threatens current treatment options. 卫生官员敦促早期发现和预防。 Health officials urge early detection and prevention.